Background: Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of squamous lung cancer with clinical features that have conflicting findings from different studies. Meanwhile, the survival time, pattern of failure after treatment, and independent prognostic factors of these patients need to be further confirmed by large-sample studies, and whether their treatment regimens need to be different from those of squamous lung cancer remains unknown. Patients and methods: Patients with PLELC diagnosed by pathology from January 2009 to December 2023 at four medical centers in China were retrospectively analyzed. Results: A total of 1106 patients with PLELC were enrolled in the study. Of these patients, 0.3% (3/1106) had brain metastasis, and 71.6% (176/204) tested positive for programmed death-ligand 1 (PD-L1). The 2-year overall survival (OS) rates of stage I, II, III, and IV were 99.4%, 97.7%, 92.7%, and 70.4%, respectively, and the 5-year OS rates were 94.8%, 88.7%, 70.6%, and 37.8%, respectively. cTNM (clinical tumor-node-metastasis) stage and baseline Epstein-Barr virus (EBV) DNA level were independent prognostic factors for both PFS and OS in PLELC patients. No statistically significant differences in progression-free survival (PFS) or OS were observed between surgery alone and surgery with adjuvant therapy in stage I and II patients or between chemoradiotherapy and combined surgery-radiotherapy in stage IIIA and IIIB patients. In stage IV patients, chemoimmunotherapy appears to have longer PFS and OS than chemotherapy alone. Conclusions: PLELC patients, with rare brain metastasis and high PD-L1 positivity, show favorable prognosis, but further research is needed to refine optimal treatment strategies for PLELC.